6-氯-2-吡啶基甲基硝酸酯 | 90500-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-2-吡啶基甲基硝酸酯
• 英文名称: 6-Chloro-2-pyridylmethyl nitrate
• 英文别名: (6-chloropyridin-2-yl)methyl nitrate
• CAS: 90500-72-4
• 化学式: C6H5ClN2O3
• 分子量: 188.57
• InChiKey: KLKMRHCMLLGCSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-氯-2-吡啶基甲基硝酸酯 、 β-环糊精 生成 (6-chloropyridin-2-yl)methyl nitrate;(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol
  参考文献：
  名称：

  UEDA, YOSHIO;ASAKURA, SOTOO;MURAKAMI, YOSHIO;SHIMOJO, FUMIO;KADO, KAZUTAK+

  摘要：

  DOI：
• 作为产物：
  描述：

  6-氯-2-羟甲基吡啶 、 硝酸 生成 6-氯-2-吡啶基甲基硝酸酯
  参考文献：
  名称：

  UEDA, YOSHIO;ASAKURA, SOTOO;MURAKAMI, YOSHIO;SHIMOJO, FUMIO;KADO, KAZUTAK+

  摘要：

  DOI：

文献信息

• Topical and oral formulations of cardiac glycosides for treating skin diseases
  申请人：Streeper Robert

  公开号：US20060205679A1

  公开（公告）日：2006-09-14

  The present invention provides method, preparation and use of a variety of pharmaceutical compositions containing at least one digitalis glycoside such as oleandrin, odoroside-A, neriifolin, proscillaridin-A, methyl-proscillaridin-A, digitoxin, digoxin alone or at least one digitalis glycoside complexed with cyclodextrins. In another aspect, the present invention provides an effective method to treat diseases in mammals. In yet another aspect, the present invention provides an effective method for treating skin diseases in a human or non-human animal.

  本发明提供了一种方法、制备和使用多种含有至少一种毛地黄苷类药物成分的药物组合物，例如奥利安定、奥多罗苷A、内里福林、普罗斯西拉里丁A、甲基普罗斯西拉里丁A、地高辛、地高辛或至少一种毛地黄苷类与环糊精络合的药物。另一方面，本发明提供了一种有效的方法来治疗哺乳动物的疾病。另一方面，本发明提供了一种有效的方法来治疗人类或非人类动物的皮肤疾病。
• Sustained-release transdermal delivery preparations
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04749574A1

  公开（公告）日：1988-06-07

  The invention relates to a sustained-release transdermal delivery preparation which comprises a slow-release microcapsule containing 2-nitroxymethyl-6-chloropyridine or its occlusion compound with .beta.-cyclodextrin and a skin-compatible base.

  本发明涉及一种持续缓释的经皮给药制剂，其包括一种慢释放微囊，其中包含2-亚硝基甲基-6-氯吡啶或其与β-环糊精的包合物和一种皮肤相容基质。
• Pyridyl alkyl nitrate compound, process for preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0100081A2

  公开（公告）日：1984-02-08

  A pyridylalkyl nitrate compound of the formula: wherein R1 is hydrogen, lower alkyl, halogen or nitroxy(lower)alkyl, one of R2 and R3 is mono (or di)-nitroxy(lower)-alkyl and the other of R2 and R3 is hydrogen or halogen, and pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising them in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

  式中的吡啶烷基硝酸酯化合物： 其中 R1 是氢、低级烷基、卤素或硝基（低级）烷基、 R2 和 R3 中的一个是单（或二）硝基（低级）烷基，R2 和 R3 中的另一个是氢或卤素、 及其药学上可接受的盐、其制备工艺以及由它们与药学上可接受的、基本上无毒的载体或赋形剂组成的药物组合物。
• An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0141300A2

  公开（公告）日：1985-05-15

  An occlusion compound of 2-nitroxymethyl-6-chloropyridine with β-cyclodextrin, a process for preparing it, pharmaceutical compositions containing it and the use thereof as a medicine.

  2-硝基甲基-6-氯吡啶与β-环糊精的闭塞化合物、制备方法、含有该化合物的药物组合物及其作为药物的用途。
• Sustained-release pharmaceutical preparation which comprised 2-nitroxy-methyl-6-chloropyridine, process for its preparation and use thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0193164A2

  公开（公告）日：1986-09-03

  A sustained-release pharmaceutical preparation which comprises 2-nitroxymethyl-6-chloropyridine or an occlusion compound thereof with β-cycloextrin, process for preparing it and use thereof as a medicament, particularly in the treatment of vascular disorder.

  一种由 2-硝基甲基-6-氯吡啶或其闭塞化合物与 β-环糊精组成的缓释药物制剂、制备方法及其作为药物的用途，特别是在治疗血管疾病方面。